Evidence map›Paper›PMID 39425834›Full record

ReviewScience China. Life sciences2025

Epidemiology of liver diseases: global disease burden and forecasted research trends.

Jia Xiao, Fei Wang, Yuan Yuan, Jinhang Gao, Lu Xiao, Chao Yan, Feifei Guo, Jiajun Zhong, Zhaodi Che, Wei Li and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jia Xiao *Department of Gastroenterology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, China. edwinsiu@connect.hku.hk.
Fei Wang *Division of Gastroenterology, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, China.
Yuan Yuan *Aier Institute of Ophthalmology, Central South University, Changsha, 410015, China.
Jinhang Gao *Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lu XiaoClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Chao YanClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Feifei GuoClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Jiajun ZhongClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Zhaodi CheClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Wei LiFaculty of Pharmaceutical Sciences, Toho University, Chiba Tokyo, 143-8540, Japan.
Tian LanLab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Frank TackeDepartment of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, 13353, Germany.
Vijay H ShahDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USA.
Cui LiDepartment of Health Sciences, National Natural Science Foundation of China, Beijing, 100085, China.
Hua WangDepartment of Oncology, The First Affiliated Hospital, Institute for Liver Diseases of Anhui Medical University, Hefei, 230032, China. wanghua@ahmu.edu.cn.
Erdan DongResearch Center for Cardiopulmonary Rehabilitation, University of Health and Rehabilitation Sciences Qingdao Hospital (Qingdao Municipal Hospital), School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, 266071, China. donged@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the global incidence, mortality, and disability-adjusted life years (DALYs) associated with various liver diseases, including alcohol-related liver disease (ALD), hepatitis B/C virus infections (HBV or HCV), liver cancer, metabolic dysfunction-associated steatotic liver disease (MASLD), and other chronic liver diseases, from the 2019 Global Burden of Disease study. Additionally, we analyzed the global trends in hepatology research and drug development. From 2000 to 2019, prevalence rates increased for ALD, MASLD and other liver diseases, while they decreased for HBV, HCV, and liver cancer. Countries with a high socio-demographic index (SDI) exhibited the lowest mortality rates and DALYs. The burden of liver diseases varied due to factors like sex and region. In nine representative countries, MASLD, along with hepatobiliary cancer, showed highest increase in funding in hepatology research. Globally, the major research categories in hepatology papers from 2000 to 2019 were cancer, pathobiology, and MASLD. The United States (U.S.) was at the forefront of hepatology research, with China gradually increasing its influence over time. Hepatologists worldwide are increasingly focusing on studying the communication between the liver and other organs, while underestimating the research on ALD. Cancer, HCV, and MASLD were the primary diseases targeted for therapeutic development in clinical trials. However, the proportion of new drugs approved for the treatment of liver diseases was relatively low among all newly approved drugs in the U.S., China, Japan, and the European Union. Notably, there were no approved drug for the treatment of ALD in the world.

Indexed as

Global Burden of DiseaseLiver DiseasesDisability-Adjusted Life YearsGlobal HealthHumansIncidenceLiver NeoplasmsPrevalencedisease burdendrug developmentGBD estimateliver diseaseresearch trend

Identifiers

PMID39425834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.